Phase 3 Bladder Cancer Trial, Recruiting NCT06214572 Sponsor: Tata Memorial Centre Condition: Bladder Cancer
Back to Bladder Cancer

Phase 3 Bladder Cancer Trial, Recruiting

NCT06214572
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with adenocarcinoma (a type of cancer) of the gallbladder, confirmed through a biopsy or tissue sample. This includes cancers starting at the neck of the gallbladder that may look similar to a nearby bile duct cancer.
  • People whose cancer has not spread to distant parts of the body, as confirmed by detailed imaging scans and, if done as part of standard care, a keyhole abdominal examination.
  • People whose cancer is locally advanced, meaning it cannot be surgically removed but meets at least one of the following conditions: the cancer has grown deeply into the liver but enough healthy liver tissue remains for safe radiation treatment; the cancer is wrapped tightly around a major blood vessel near the liver; or the cancer is blocking the bile ducts and causing jaundice in a specific way (confirm with trial site for exact classification details).
  • People whose cancer has either stayed stable or partially shrunk after 3 months of chemotherapy treatment based on a drug called Gemcitabine.
  • People who are over 18 years of age.
  • People who are well enough to receive chemotherapy, based on a standard fitness scale used by doctors (rated 0, 1, or 2 out of 4, where lower numbers mean fewer limitations on daily activity).
  • People whose blood counts, kidney function, and liver function are within acceptable ranges to safely receive chemotherapy — the trial site will check specific blood test results to confirm this.

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body, including lymph nodes that are not close to the original tumour.
  • People who have previously had radiation therapy to the abdomen.
  • People who have had another type of cancer in the past or present that was not fully cured, or that was treated but has not been in remission for more than 5 years — except for certain skin cancers or early-stage cervical cancer that were fully treated.
  • People who are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Shivakumar Gudi, MD, Assistant Professor, Radiation Oncology

Phone: +912224177000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tata Memorial Centre
Registry
ClinicalTrials.gov
Start date
7 March 2024
Est. completion
21 July 2029

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Median overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov